Celator Pharmaceuticals, a privately held pharmaceutical company developing novel products based on proven combinations of chemotherapeutic drugs, today announced that it raised in excess of $22.5 million in a Series C private equity financing. The proceeds will be used to fund Phase 2 studies of CPX-351 (a liposomal formulation of cytarabine:daunorubicin) in patients with acute […]
Less
More
Agios Pharmaceuticals Inc., the first biopharmaceutical company focused on discovering and developing novel drugs that target key metabolic pathways to fundamentally disrupt cancer cells’ ability to grow and survive, today announced that it has closed a $33 million Series A financing. Agios Pharmaceuticals is the first biopharmaceutical company dedicated to the development of novel therapeutics […]
Gemin X Pharmaceuticals, Inc., a privately held pharmaceutical company focused on developing novel treatments for cancer, today announced the closing of a $38 million tranched Series C financing. Gemin X’s lead product, obatoclax (GX15-070), a small molecule, pan Bcl-2 inhibitor, is currently in Phase 2 clinical trials in both hematological and solid tumor cancers. Gemin […]
IRX Therapeutics, Inc. a privately-held company dedicated to the discovery and development of proprietary drugs for the treatment of cancer and viral diseases, today announced that it has raised $25 million through a Series A Preferred Stock offering. The Company’s product platform seeks to restore an effective cellular immune response for the treatment of advanced […]
NGN Capital announced today the formation of ACT Biotech Inc., a new company dedicated to developing and commercializing targeted oral cancer drugs. ACT Biotech has entered into a license agreement with Bayer HealthCare LLC for a portfolio of clinical and early stage oncology assets. In conjunction with the agreement, ACT has raised $12 million in […]
Auspex Pharmaceuticals Inc., a developer of next-generation medicines with improved safety and performance through the targeted deuteration of clinically validated drugs, today announced a $13.875 million Series B financing. Auspex Pharmaceuticals, founded in 2001, is a developer of next-generation medicines with improved safety and performance and a pioneer in the targeted application of deuterium chemistry […]
Apoptos Inc., an oncology research and development company, today announced that it has secured $28 million in funding. It will be used to advance Apoptos’ portfolio of small molecule drugs that are directed at inducing tumor cell apoptosis, also known as programmed cell death. Apoptos is pioneering its anticancer platforms in close collaborations with preeminent […]
Apogenix GmbH, a biopharmaceutical company developing novel drugs based on the targeted modulation of apoptosis (programmed cell death), today announced the closing of its second financing round. Apoptosis is a natural and highly controlled mechanism to clear the body of old, damaged or abnormally transformed cells. In many disease indications, this process has become out […]
Concert Pharmaceuticals, Inc., announced the closing of a $37 million Series C financing today. CoNCERT Pharmaceuticals, Inc. is dedicated to creating new medicines through a novel scientific approach utilizing the naturally-occurring element deuterium. CoNCERT applies its innovative platform to modify specific properties of validated drug molecules, yielding a rich pipeline of new chemical entities (NCEs). […]
Constellation Pharmaceuticals, the first biopharmaceutical company focused on discovering and developing novel drugs targeting selective regulators of epigenetic function, today announced that it has closed a $32 million Series A financing. “Through Epigenetics, which represents a breakthrough in our understanding of biology at an entirely new level, at the interface between DNA and gene expression, […]
small molecule
BioTechnology